• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Trends in volume-regulated anion channel (VRAC) research: visualization and bibliometric analysis from 2014 to 2022
Conclusion: The aim of this bibliometric analysis is to provide an overall perspective for research on VRAC. VRAC has become a topic of increasing interest, and our analysis shows that it continues to be a prominent area. This study offers insights into the investigation of VRAC channel and may guide researchers in identifying new directions for future research.PMID:37538172 | PMC:PMC10394876 | DOI:10.3389/fphar.2023.1234885
Source: Atherosclerosis - August 4, 2023 Category: Cardiology Authors: Tianbao Liu Yin Li Dawei Wang Tobias Stauber Jiajun Zhao Source Type: research

Inflammation May Be the Culprit Behind Our Deadliest Diseases
In the early days of my medical residency, I met a man whom we’ll call Jason. He arrived to our emergency room on a holiday, nonchalant yet amiable, and complained of mild chest pain. Jason was tall and trim, with a strong South Boston accent and fingertips still faintly stained from his last home-improvement project. He was only 45 years old, but he looked much younger. He didn’t smoke, barely drank alcohol, and his cholesterol levels had always been normal. No one in his family had a history of heart disease. He asked us if we could work quickly—he wanted to be home for dinner with his daughters. [time-...
Source: TIME: Health - April 11, 2023 Category: Consumer Health News Authors: Shilpa Ravella Tags: Uncategorized freelance health Source Type: news

Continuous ingestion of sodium chloride solution promotes allergen absorption and may exacerbate allergy symptoms on ovalbumin-induced food allergy in mice
In this study, we investigated the effect of continuous ingestion of sodium chloride (NaCl) on allergy symptoms using a mouse model of food allergy. BALB/c mice were divided into four groups of 6-8 animals each. The control-water group (CW) and sensitization-water group (SW) groups were provided free access to water, and the control-1% NaCl group (CS) and sensitization-1% NaCl group (SS) groups were provided a 1% NaCl solution. The SW and SS groups were sensitized with 50 µg ovalbumin (OVA) at 2 timepoints by intraperitoneal injection. After oral administration of OVA, anaphylactic response was measured and blood was coll...
Source: Drug Discoveries and Therapeutics - February 27, 2023 Category: Drugs & Pharmacology Authors: Mamoru Tanaka Rui Lu Hana Kozai Source Type: research

Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancer
CONCLUSION: S-CSF2-Ab was useful for the diagnosis of atherosclerosis-related AIS, AMI, DM, and CKD and could discriminate poor prognosis, especially in p53-Ab-negative CRC.PMID:36844744 | PMC:PMC9954151 | DOI:10.3389/fcvm.2023.1042272
Source: Atherosclerosis - February 27, 2023 Category: Cardiology Authors: Shu-Yang Li Yoichi Yoshida Masaaki Kubota Bo-Shi Zhang Tomoo Matsutani Masaaki Ito Satoshi Yajima Kimihiko Yoshida Seiichiro Mine Toshio Machida Aiko Hayashi Minoru Takemoto Koutaro Yokote Mikiko Ohno Eiichiro Nishi Kenichiro Kitamura Ikuo Kamitsukasa Hir Source Type: research

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Physical inactivity and non-communicable disease burden in low-income, middle-income and high-income countries
Conclusion The global burden associated with physical inactivity is substantial. The relative burden is greatest in high-income countries; however, the greatest number of people (absolute burden) affected by physical inactivity are living in middle-income countries given the size of their populations.
Source: British Journal of Sports Medicine - January 3, 2022 Category: Sports Medicine Authors: Katzmarzyk, P. T., Friedenreich, C., Shiroma, E. J., Lee, I.-M. Tags: Editor's choice, Press releases, BJSM Original research Source Type: research

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Prevalence and economic burden of major comorbidities in multiple sclerosis
ConclusionsOur study provides evidence of the burden of comorbidities in MS. Comorbidity is common in MS and produce additive costs.Key messagesThe use of administrative data for tracking the MS comorbidity could help knowledge gaps.When additivity situation is involved, preventive policies could lead to monetary savings.
Source: The European Journal of Public Health - October 20, 2021 Category: General Medicine Source Type: research

Physical inactivity and non-communicable disease burden in low-income, middle-income and high-income countries
CONCLUSION: The global burden associated with physical inactivity is substantial. The relative burden is greatest in high-income countries; however, the greatest number of people (absolute burden) affected by physical inactivity are living in middle-income countries given the size of their populations.PMID:33782046 | DOI:10.1136/bjsports-2020-103640
Source: British Journal of Sports Medicine - March 30, 2021 Category: Sports Medicine Authors: Peter T Katzmarzyk Christine Friedenreich Eric J Shiroma I-Min Lee Source Type: research

Pages: 1  2  3